Pulmonary Function Testing (PFT) is an integral tool in the diagnosis, management, and monitoring of respiratory diseases. Given the complexity of these tests and the wealth of data they generate, healthcare professionals may find the interpretation challenging. This article aims to provide a comprehensive guide to interpreting PFTs.
The fundamental parameters in PFT interpretation include Forced Vital Capacity (FVC), Forced Expiratory Volume in the first second (FEV1), and the ratio of the two (FEV1/FVC). Changes in these values can indicate obstructive or restrictive lung diseases. Additionally, the Total Lung Capacity (TLC) can provide insight into the severity of the condition.
Spirometry is the first step in PFT interpretation. An FEV1/FVC ratio less than 70% suggests obstructive pathology, such as COPD or asthma. Conversely, a normal or increased FEV1/FVC ratio with reduced FVC and TLC points towards restrictive diseases like pulmonary fibrosis.
Beyond spirometry, PFTs provide information on lung volumes and gas exchange. A reduced TLC confirms a restrictive pattern, while increased Residual Volume (RV) is indicative of air trapping in obstructive diseases. Diffusing capacity of the lungs for carbon monoxide (DLCO) is a critical measure of gas exchange, with reductions suggesting emphysema or interstitial lung disease.
Interpreting PFTs requires integration of all parameters. For example, a patient with reduced FEV1/FVC and DLCO, but normal lung volumes, may have early COPD. A comprehensive understanding of these nuances can improve diagnostic accuracy and patient management.
While PFT interpretation can be complex, a systematic approach can simplify the process. Understanding basic parameters, interpreting spirometry, assessing lung volumes and gas exchange, and integrating findings can enhance our diagnostic capabilities and ultimately improve patient care.
1.
New guidelines for radiation therapy for HPV-associated head and neck cancer
2.
Cancer mortality continuing to decline, says report
3.
Getting Lung Cancer Screening Staff Involved Improved Tobacco Cessation
4.
There has been a recent decrease in the risk of a recurrence of colorectal cancer in stage I to III cases.
5.
Adding Targeted Agent to Perioperative Therapy for RCC May Improve Disease Control
1.
Different Types of Blood Dyscrasias
2.
Pembrolizumab Plus Lenvatinib in EBV-Associated Advanced Intrahepatic Cholangiocarcinoma: Case Study
3.
Lymphomatoid Papulosis: What You Need to Know
4.
MASLD and Cancer Risk: Pathogenic Links and Clinical Implications Reviewed
5.
Rare Malignant Ovarian Tumors: A Comprehensive Review for Clinicians
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Clinical Insights in Oncology
2.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
3.
Exploring Best Possible Treatment Strategies in Advanced Urothelial Carcinoma- A Panel Discussion
4.
Navigating the Complexities of Ph Negative ALL - Part XI
5.
Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation